Table 1.
Baseline clinical characteristics by different outcomes and treatment groups
| |
All |
Survival |
Mortality |
p |
Telbivudine |
Entecavir |
p |
|---|---|---|---|---|---|---|---|
| Patient no | 21 | 17 | 4 | 9 | 12 | ||
| Age |
48 (28–71) |
49 (28–71) |
36.5 (29–51) |
0.226 |
48 (29–65) |
47 (28–71) |
0.859 |
| Gender |
|
|
|
1.000 |
|
|
1.000 |
| Male |
18 |
14 |
4 |
8 |
10 |
||
| Female |
3 |
3 |
0 |
1 |
2 |
||
| LdT/ETV |
9/12 |
7/10 |
2/2 |
1.000 |
− |
− |
− |
| Mortality |
− |
− |
− |
− |
2 |
2 |
1.000 |
| HBeAg+ |
9 |
7 |
2 |
1.000 |
3 |
6 |
0.660 |
| Cirrhosis |
3 |
2 |
1 |
0.489 |
1 |
2 |
1.000 |
| Ascites |
3 |
1 |
2 |
0.080 |
1 |
2 |
1.000 |
| Encephalopathy |
1 |
1 |
0 |
0.190 |
1 |
0 |
0.429 |
| FU (M) |
19.4 (0.8–28.2) |
25.0 (4.0–28.2) |
1.45 (0.8–2.5) |
0.002 |
5.1 (1.9–28.2) |
24.7 (0.8–27.7) |
0.722 |
| Albumin |
3.49 (2.5–4.9) |
3.6 (2.5–4.9) |
2.95 (2.5–3.3) |
0.020 |
3.6 (2.9–4.2) |
3.4 (2.5–4.9) |
0.477 |
| ALT |
1270 (146–2480) |
1270 (211–2480) |
1197 (146–2247) |
0.929 |
1523 (211–2480) |
870 (146–2247) |
0.177 |
| Bilirubin T |
9.2 (2.1–33.1) |
7.7 (2.1–16.8) |
20.6 (11.9–33.1) |
0.007 |
8.6 (2.1–20.4) |
10.25 (2.2–33.1) |
0.356 |
| Creatinine |
0.68 (0.39–1.46) |
0.71 (0.47–1.34) |
0.48 (0.39–1.46) |
0.165 |
0.71 (0.47–1.05) |
0.63 (0.39–1.46) |
0.972 |
| eGFR |
|
|
|
|
|
|
|
| MDRD |
116 (53–254) |
116 (53–183) |
194.5 (54–254) |
0.106 |
116 (73–201) |
127 (53–254) |
0.831 |
| CKD-EPI |
111.1 (52.9–156.7) |
110.1 (52.9–131.1) |
138.2 (59.8–156.7) |
0.152 |
112 (77.8–148) |
110.6 (52.9–156.7) |
0.722 |
| Platelet (103) |
148 (44–253) |
148 (62–253) |
121.5 (44–174) |
0.244 |
174 (44–251) |
121.5 (62–253) |
0.188 |
| INR |
1.6 (1.3–3.5) |
1.5 (1.3–2.3) |
3.3 (2.6–3.5) |
0.002 |
1.5 (1.3–3.1) |
1.6 (1.4–3.5) |
0.773 |
| AFP |
65.7 (4.1–650.7) |
49.4 (4.1–477.2) |
109.5 (27.9–650.7) |
0.325 |
27.9 (4.2–238.3) |
162.1 (4.1–650.7) |
0.088 |
| HBV DNA (log10 cps/ml) |
8.04 (4.3–9.68) |
8.16 (5.22–9.68) |
5.06 (4.30–8.20) |
0.031 |
8.04 (4.97–9.47) |
8.04 (4.30–9.68) |
0.886 |
| MELD score | 20 (13–37) | 19 (13–28) | 31.5 (26–37) | 0.003 | 19 (14–31) | 20 (13–37) | 0.412 |
Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.